Anzeige
Mehr »
Mittwoch, 04.02.2026 - Börsentäglich über 12.000 News
Revolutionäre Entwicklung im Megatrend - Der KI-Durchbruch für Pflege und Sicherheit!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41APT | ISIN: CA75103L3092 | Ticker-Symbol: 7JO0
Tradegate
03.02.26 | 15:37
0,111 Euro
-10,84 % -0,014
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
RAKOVINA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
RAKOVINA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1210,13418:08
0,1210,13417:59

Aktuelle News zur RAKOVINA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16:18Rakovina Therapeutics Inc (2): Rakovina talks inbound interest for kt-30001
10:06Rakovina Therapeutics Inc: Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit70Highlights: Strategic Validation: Industry feedback confirms Rakovina's approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage...
► Artikel lesen
FrRakovina Therapeutics Inc (2): Rakovina Therapeutics debentures extended3
28.01.Rakovina Therapeutics Inc (2): Rakovina Therapeutics appoints Oishi as CEO, director6
27.01.Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring333Proposed $1.0 million Convertible Debenture and concurrent $500,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital...
► Artikel lesen
08.01.Rakovina Therapeutics Inc (2): Rakovina signs new deal with Variational AI1
08.01.Rakovina Therapeutics Inc: Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors5
17.12.25Rakovina Therapeutics Inc: Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California11
RAKOVINA THERAPEUTICS Aktie jetzt für 0€ handeln
10.12.25Rakovina Therapeutics Inc (2): Rakovina to host webinar with Variational AI on Dec. 172
01.12.25Rakovina Therapeutics Inc (2): Rakovina's Q3 R&D expenses at $1.1-million19
01.12.25Rakovina Therapeutics reports Q3 results3
01.12.25Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update241All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V:...
► Artikel lesen
29.11.25Rakovina Therapeutics Inc (2): Rakovina debentureholders consent to maturity extension2
29.11.25Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program264VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies...
► Artikel lesen
24.11.25Rakovina Therapeutics Inc (2): Rakovina talks ATR/mTOR dual inhibitor preclinical data2
24.11.25Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting196VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing cancer therapies...
► Artikel lesen
24.11.25Rakovina Therapeutics Inc: Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting1
18.11.25Rakovina Therapeutics Inc: Rakovina Therapeutics' President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit2
10.11.25Rakovina Therapeutics Inc: Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting9
29.08.25Rakovina Therapeutics reports Q2 results36
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1